Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18-Month MDR-TB Regimen Study
NCT03830671Phase 4Completed
- Sponsor
- Beijing Chest Hospital
- Start
- Mar 2019
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of amikacin, moxifloxacin, pyrazinamide in Tuberculosis (TB), sponsored by Beijing Chest Hospital. Started Mar 2019; status: completed.
02
Drugs
amikacinmoxifloxacinpyrazinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03830671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830671.